Article Text

Download PDFPDF
EP712 Ovarian borderline tumors with invasive peritoneal implants: a long term follow-up study of 30 patients
  1. L Gaichies1,
  2. A Maulard1,
  3. C Genestie2,
  4. P Pautier3,
  5. E Bentivegna1,
  6. A Leary3,
  7. C Chargari4,
  8. P Morice1 and
  9. S Gouy1
  1. 1Surgery
  2. 2Pathology
  3. 3Medical Oncology
  4. 4Brachytherapy, Institut Gustave Roussy, Villejuif, France


Introduction/Background Ovarian serous borderline tumors with invasive peritoneal implants (SBOT-IPI) are associated with serous low grade carcinomas (SLGC) in the 2016 WHO classification of ovarian neoplasms. Even if SBOT-IPI can relapse as SLGC in 30% of cases, long term survival is not well known. The aim of this study was to describe the frequency and the characteristics of the recurrences of OSBT-IPI.

Methodology Retrospective study of patients referred to our institution, from 1971 to 2018, for a SBOT-IPI with a minimal follow-up of 12 months.

Results 30 patients were identified; the median age at diagnosis was 36,5 [19–72] year. FIGO stage was up to IIIA for 26 patients and the average number of peritoneal areas involved was 4,5 [1–12]. The median follow-up was 106,6 [12–366] months. Twelve patients (40%) developed an invasive relapse (4 as SBOT-IPI and 7 as SLGC) with an average time of 53,6 [10,1–175,8] months. In this group, the mean age was 45,3 [23–72] year old at first diagnosis. The initial stage was up to IIIB in 75% of the cases and the average number of peritoneal areas involved was 5,2 [1–12]. Two patients died due to recurrence, one had a recurrence as SBOT-IPI 6 years after and one as SLGC 10 years after.

Conclusion Relapsing as an invasive disease were more frequent than reported in other series and seems to be associated with the initial FIGO stage and with the number of peritoneal areas involved in the initial diagnosis. However, in this long term follow-up study, overall mortality of SBOT-IPI seems lower than mobility rate of SLGC. This study highlights that SBOT-IPI long term survival is poorly known. Finally, the prognosis of the SBOT-IPI should not be associated with the SLGC.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.